1176405-02-9 Usage
Uses
Used in Pharmaceutical Synthesis:
4,5,6,7-Tetrahydro-5-azaindole is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drug candidates with potential therapeutic applications.
Used in Organic Chemistry:
THAIA is utilized as a versatile building block in organic chemistry, allowing for the creation of a wide range of biologically active compounds due to its structural flexibility and ease of synthesis.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4,5,6,7-Tetrahydro-5-azaindole is employed as a valuable component in the design of compounds with specific pharmacological properties, such as antimicrobial and antifungal activities, which are crucial for addressing various medical needs.
Used in Antimicrobial and Antifungal Agents Development:
4,5,6,7-Tetrahydro-5-azaindole is used as a precursor in the development of antimicrobial and antifungal agents, leveraging its inherent bioactivity to combat a range of microbial infections.
Check Digit Verification of cas no
The CAS Registry Mumber 1176405-02-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,7,6,4,0 and 5 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1176405-02:
(9*1)+(8*1)+(7*7)+(6*6)+(5*4)+(4*0)+(3*5)+(2*0)+(1*2)=139
139 % 10 = 9
So 1176405-02-9 is a valid CAS Registry Number.
1176405-02-9Relevant articles and documents
Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2
Troxler, Thomas,Greenidge, Paulette,Zimmermann, Kaspar,Desrayaud, Sandrine,Drückes, Peter,Schweizer, Tatjana,Stauffer, Daniela,Rovelli, Giorgio,Shimshek, Derya R.
, p. 4085 - 4090 (2013/07/25)
Mutations in leucine-rich repeat kinase-2 (LRRK2) are the most common genetic cause of Parkinson's disease (PD). The most frequent kinase-enhancing mutation is the G2019S residing in the kinase activation domain. This opens up a promising therapeutic avenue for drug discovery targeting the kinase activity of LRRK2 in PD. Several LRRK2 inhibitors have been reported to date. Here, we report a selective, brain penetrant LRRK2 inhibitor and demonstrate by a competition pulldown assay in vivo target engagement in mice.